Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Resilience Despite Relapse
Papers: 14 Aug 2015 - 21 Aug 2015
Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis.
Newly Identified Gait Patterns in Patient With Multiple Sclerosis May Be Related to Push-Off Quality.
Papers: 8 May 2015 - 15 May 2015
Plasma Osteopontin Levels: A New Marker for MS?
Modelling the Impact of Persistence Improvements with an Electronic Injection Device on Escalation to 2nd Line Treatment in Patients with Relapsing Remitting Multiple Sclerosis (RRMS).
NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
Do evoked potentials contribute to the functional follow-up and clinical prognosis of multiple sclerosis?
Spinal Vision
Papers: 22 Dec 2015 - 29 Dec 2015
Papers: 11 Sep 2015 - 18 Sep 2015
Papers: 17 Jul 2015 - 24 Jul 2015
European Multiple Sclerosis Platform 2016 Spring Conference
Evaluation of Disability Progression as an Endpoint in Clinical Trials for Relapsing-Remitting Multiple Sclerosis (RRMS): Comparison of the Define and Confirm Studies.
A Real-World Assessment of Annual Multiple Sclerosis Prevalence and Disease-Modifying Drug Treatment Rates Using an Administrative Claims Database.
Cost-Effectiveness of Subcutaneous Verse Intramuscular Interferon Beta-1A In Portugal Based on the Findings of Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remitting Multiple Sclerosis.
Susac's syndrome: Leptomeningeal enhancement on 3D FLAIR MRI.
Accurate MS Information for Your Patients
The Indirect Costs of Multiple Sclerosis Associated With Absenteeism In Poland.
Cross-disease transcriptomics: Unique IL-17A signaling in psoriasis lesions and an autoimmune PBMC signature.
Resisting Arrest
Best Practices and Key Challenges in Cost-Effectiveness Modelling of Multiple Sclerosis Therapies.
Histamine and Immune Biomarkers in CNS Disorders.
A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.

Pages